Loading clinical trials...
Loading clinical trials...
Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients
Conditions
Interventions
Riociguat (Adempas, BAY63-2521)
Placebo
Locations
10
United States
Birmingham, Alabama, United States
Denver, Colorado, United States
St Louis, Missouri, United States
Bruxelles - Brussel, Belgium
Toronto, Ontario, Canada
Paris, France
Start Date
September 30, 2014
Primary Completion Date
January 17, 2017
Completion Date
September 22, 2017
Last Updated
November 7, 2023
NCT04469439
NCT06154447
NCT06984679
NCT02417740
NCT05359991
NCT07484607
Lead Sponsor
Bayer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions